The basics: whether you can get a GLP-1 covered has almost nothing to do with whether you could benefit from it. It comes down to which drug you are asking for, what that drug is approved to treat, who writes your plan, and which state you live in. Below is what to expect from each type of plan, and what the drug costs if the answer is no.
What actually decides whether a GLP-1 is covered?
Two things decide it: what the drug is approved to treat, and who writes your plan.
Four of these medications are approved for weight loss: Wegovy, Zepbound, Saxenda and Foundayo are approved for chronic weight management. Ozempic, Mounjaro and Rybelsus are approved for type 2 diabetes. A drug can be prescribed for a use the FDA never approved, and that is where most coverage fights start. A drug is approved by the FDA for specific uses, and those uses go on the label. A doctor may still prescribe it for something else, using their own clinical judgment. That is off-label prescribing, it is legal, and it is common across all of medicine.
So a prescription for Ozempic to treat weight is off-label, while a prescription for Wegovy to treat weight is not. Same molecule, different approval. Starting a GLP-1 goes through which drug is approved for what, and our comparison of the medications puts them side by side. Your doctor is allowed to write either one. Your insurer decides separately, and it generally prices by what the drug is approved to treat, so an off-label request is the harder ask.
So coverage for diabetes is fairly common, and coverage for weight management is the contested one. The rest comes down to who your plan comes from.
What if you have a commercial or employer plan?
Most employer plans exclude weight-loss coverage, and many that include it attach conditions.
In 2025, about 19% of firms with 200 or more workers covered GLP-1s for weight loss. Among firms with 5,000 or more, it was about 43%. Bigger employers are much likelier to cover it.
Covered sometimes comes with certain requirements. Among employers who do cover these medications, about a third attach a requirement before you qualify. That usually means meeting a professional, which can be a dietitian, psychologist, case worker or therapist, or enrolling in a lifestyle or weight-loss program. You can meet the medical criteria and still be turned down for skipping a step you did not know existed.
Structured lifestyle support does help these drugs work, and the trials we grade in the evidence on care gaps usually included it. What plans rarely do is make the program easy to reach. If your plan requires one, ask them to name the specific programs they accept, because “see a dietitian” and “complete our approved program” are different requirements with different waiting lists.
Three other conditions come up often.
- A BMI threshold. Plans set a minimum BMI to qualify, and it does not always match the one on the drug’s label. Ask what number your plan uses and whether a weight-related condition like high blood pressure or sleep apnea lowers it.
- Step therapy. You may have to try a cheaper option first and show it did not work before the plan will approve the drug you asked for. Ask what counts as a failed trial and how long it has to run.
- Documented history. Plans often want records of previous weight-loss attempts, which usually means notes from a clinician rather than your own account. If you have tried before, ask whether those visits are in your records.
None of these is a refusal. Each is a box, and the plan will tell you which boxes it uses if you ask.
How to find out where you stand. Your plan’s formulary is the list of drugs it pays for, and it is the document that answers this. Three ways to reach it:
- Call the member number on your insurance card and ask whether the drug is on the formulary, and what conditions apply
- Search your plan’s member portal by drug name, checking both the brand and the molecule
- Ask the prescribing office, since many have staff who do this daily
Ask about the conditions, not just whether it is covered or not. A drug can sit on the formulary and still require a BMI threshold, a lifestyle program, or prior authorization first. Prior authorization means your plan will not pay until your prescriber submits paperwork showing you meet the plan’s criteria, and the plan approves it. Our insurance checker is a faster starting point.
What if you have Medicare?
Medicare still cannot cover these drugs for weight loss, but since 1 July 2026 a separate temporary program has offered a route at $50 a month.
Part D is the prescription drug side of Medicare. By a decades-old statute, it cannot pay for a drug used for weight loss. These drugs are covered under Part D for diabetes and for heart risk, but not for obesity itself. That statute has not changed.
What changed is that CMS started something alongside it. The Medicare GLP-1 Bridge launched on 1 July 2026 and is scheduled to run to 31 December 2027. It offers Wegovy, Zepbound (KwikPen only) or Foundayo for a flat $50 a month. It sits outside normal Part D coverage rather than replacing the exclusion, which makes it a temporary program, not Medicare coverage.
The eligibility rules are narrow. You need Part D coverage and you must be 18 or over. Beyond that there are three ways to qualify on BMI, and CMS assesses them as of the day you started the medication, not the day the paperwork goes in:
- A BMI of 35 or higher, on its own.
- A BMI of 30 or higher plus heart failure with preserved ejection fraction, uncontrolled high blood pressure (above 140 systolic or 90 diastolic despite taking two blood-pressure medicines), or chronic kidney disease at stage 3a or above.
- A BMI of 27 or higher plus pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.
Three things rule you out. You cannot already have received a GLP-1 through your Part D plan this year, for any reason. You cannot have a diagnosis of type 2 diabetes, moderate-to-severe sleep apnea, or noncirrhotic MASH with moderate-to-advanced liver scarring, because those conditions are already covered under Part D and the Bridge exists to fill the gap where nothing else pays. And the prescription itself has to be for weight management: if it is written to reduce cardiovascular risk, it belongs with your Part D plan instead. Having heart disease does not disqualify you, but being prescribed the drug for it does.
Three catches. The $50 does not count toward your Part D deductible or your out-of-pocket cap. Your prescriber has to file for approval before you can fill it. And Extra Help cannot be applied to it.
Extra Help, also called the Part D Low-Income Subsidy, is the federal program that lowers drug costs for people with limited income and savings. If you rely on it for your other prescriptions, it will not bring this $50 down.
Manufacturer savings cards, the ones that bring commercial-plan costs down to around $25, exclude anyone on government insurance, so that route is closed to you. For what changed this year and what may change next, our Medicare coverage update tracks it.
What if you have Medicaid?
A minority of state Medicaid programs cover these for weight, and the number has been falling.
As of January 2026, 13 state Medicaid programs covered GLP-1s for obesity, down from 16 in October 2025. California, New Hampshire, Pennsylvania and South Carolina all ended coverage on 1 January 2026, citing cost.
Coverage for type 2 diabetes is a separate question, and it is much more common. If you have a diabetes diagnosis, the answer is likelier to be yes regardless of what your state does about obesity.
Medicaid is run by states, not federally. That is why there is no single answer and no national list to check. Each state decides which drugs its program pays for, and states have been revisiting that decision as costs rise. A state that covered these last year may not this year.
Finding your state’s answer. Search for your state’s name with “Medicaid preferred drug list,” which is the document that lists what the program pays for. Your state’s Medicaid agency site will carry it, and the member services number on your Medicaid card can tell you directly. Ask the same question as everyone else on this page: not just whether it is covered, but what conditions apply.
What if you are paying cash, or your plan says no?
The list price is not what most people pay, and the cheapest advertised prices come with eligibility rules.
Both manufacturers now sell directly to people paying cash, well below list. Here is what each route costs a month, as of 2026.
| How you pay | Roughly what it costs a month |
|---|---|
| List price | $1,000 to $1,350 |
| Cash, direct from the manufacturer | $350 to $500 |
| Commercial insurance plus a savings card | As low as $25 |
From 1 January 2027, Novo Nordisk has announced a list price of $675 a month for Wegovy, Ozempic and Rybelsus. That helps most if your costs are tied to the list price. On a high-deductible plan, or with coinsurance, they usually are. Novo has said its direct self-pay prices are not changing. So if you are already paying cash, the January date is unlikely to move your number.
If you have commercial insurance, a manufacturer savings card can bring the monthly cost to around $25. The catch is who qualifies. These cards exclude anyone on Medicare, Medicaid, VA or TRICARE. They also carry expiry dates that change each plan year. The current terms for each one sit on its savings page, like Wegovy’s and Zepbound’s. The lowest advertised price is unavailable to a large share of the people most likely to need it.
Compounded versions, which were much cheaper, have largely closed off since the shortages resolved. Per-drug pricing lives on each medication’s own page: Wegovy, Zepbound, Ozempic, Mounjaro and Rybelsus. All of these figures are current as of 2026 and change frequently, so check them before you commit to anything.
What if your plan requires prior authorization, or turns you down?
Prior authorization is a delay with a clock on it, not a refusal.
Your prescriber submits paperwork showing you meet the plan’s criteria, and the plan has to answer. For a treatment you have not received yet, it must notify you in writing, with its reasons, within 15 days.
If the answer is no, you have 180 days from that notice to file an internal appeal. The plan then has 30 days to complete it when the service has not been received. If your situation is urgent, you can ask for an independent external review without waiting for the internal appeal to finish, and you can file both at the same time.
Those rules cover commercial and marketplace plans. Medicare and Medicaid run their own appeals processes, with different steps and different deadlines.
What appealing actually achieves. You will see a figure online saying most prior-authorization denials get overturned on appeal. We could not find a source for it, and the best available data points the other way. In ACA marketplace plans, fewer than 1% of denied claims are appealed at all, and of the appeals that are filed, insurers upheld their own denial in 56% of cases in 2023 and 66% in 2024. That figure covers all denied claims rather than GLP-1 requests specifically, so treat it as the shape of the system rather than your odds.
Appeal anyway if you are denied. A third or more do succeed, and what it costs you is time. But the stronger lever sits earlier. Ask the plan for its written criteria before your prescriber submits anything, and make sure the paperwork shows you meeting them line by line. A plan can act on documentation. It cannot act on how much you want the drug.
Why is it this hard to get covered?
Because these drugs are judged worth it for one patient and unaffordable for everyone at once. Every payer builds a gate, and the gates are different.
In December 2025, the Institute for Clinical and Economic Review, an independent group that assesses whether treatments are worth their price, judged that these medications now sit below its value benchmarks at the prices insurers actually pay. That reversed its 2022 verdict. In the same report it warned that the health system would be strained to provide them affordably at scale. England’s National Institute for Health and Care Excellence landed in a similar place. It recommends tirzepatide, and it rations access through specialist services and a phased multi-year rollout.
So a denial is usually a budget decision made about a population and applied to you. Your plan is not weighing whether you personally would benefit. It is applying a rule written to control how many people qualify.
A year ago, most people on Medicare had no route to these drugs at all. Now there is one, narrow and temporary, but real. List prices are scheduled to fall in January. Some state Medicaid programs have gone backward while others have gone forward.
So the answer you get today is not the permanent answer, and it is worth asking again when your plan year turns over. The people who end up covered are usually not the ones with the strongest case. They are the ones who found out the exact rule their plan uses, and met it on paper.
Sources and review
Which drug is approved for what
- US FDA, Center for Drug Evaluation and Research. Summary Review, NDA 215256, Wegovy (semaglutide 2.4 mg injection). Approved June 4, 2021. accessdata.fda.gov
- US FDA, Center for Drug Evaluation and Research. Summary Review, NDA 217806, Zepbound (tirzepatide). accessdata.fda.gov
- US FDA, Center for Drug Evaluation and Research. Summary Review, NDA 209637, Ozempic (semaglutide). Approved December 5, 2017. accessdata.fda.gov
Employer and Medicaid coverage
- KFF. 2025 Employer Health Benefits Survey. kff.org (retrieved July 28, 2026)
- KFF. Medicaid Coverage of and Spending on GLP-1s. kff.org (retrieved July 28, 2026)
Medicare
- Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge. Effective July 1, 2026 through December 31, 2027. cms.gov (retrieved July 28, 2026)
- KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge. kff.org (retrieved July 28, 2026)
Prices and self-pay
- Novo Nordisk. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus. February 24, 2026, effective January 1, 2027.
- Novo Nordisk. NovoCare Pharmacy self-pay pricing (retrieved 2026)
- Eli Lilly. LillyDirect self-pay pricing for Zepbound (retrieved 2026)
Value and rationing
- Institute for Clinical and Economic Review. Obesity management assessment, December 2025.
- National Institute for Health and Care Excellence. Tirzepatide for managing overweight and obesity, TA1026.
Not yet medically reviewed. This page is in editorial review. A named clinical reviewer and review date are required before it is indexed.